Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross‐over controlled trial in a rare disease

Bideau, 1989, Epidemiological investigation of Rendu‐Osler disease in France: its geographical distribution and prevalence, Popul, 44, 3 Shovlin, 2000, Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu‐Osler‐Weber syndrome), Am J Med Genet, 91, 66, 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P Plauchu, 1989, Age‐related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population, Am J Med Genet, 32, 291, 10.1002/ajmg.1320320302 McAllister, 1994, Endoglin, a TGF‐beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1, Nat Genet, 8, 345, 10.1038/ng1294-345 Johnson, 1996, Mutations in the activin receptor‐like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2, Nat Genet, 13, 189, 10.1038/ng0696-189 Gallione, 2004, A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4), Lancet, 363, 852, 10.1016/S0140-6736(04)15732-2 Haitjema, 1996, Epistaxis in hereditary haemorrhagic telangiectasia, Rhinology, 34, 176 Karapantzos, 2005, Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR‐QoL questionnaire, Eur Arch Otorhinolaryngol, 262, 830, 10.1007/s00405-004-0911-0 Folz, 2005, Natural history and control of epistaxis in a group of German patients with Rendu‐Osler‐Weber disease, Rhinology, 43, 40 Klepfish, 2001, Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia, Arch Intern Med, 161, 767, 10.1001/archinte.161.5.767 Sabba, 2001, Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia, N Engl J Med, 345, 926, 10.1056/NEJM200109203451216 Lozano, 2002, Tranexamic acid in hereditary hemorrhagic telangiectasia, N Engl J Med, 346, 457, 10.1056/NEJM200202073460620 Fernandez‐L, 2007, Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK‐1/endoglin pathway in endothelial cells, J Thromb Haemost, 97, 254, 10.1160/TH06-07-0373 Shovlin, 2007, Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism, J Thromb Haemost, 98, 1031, 10.1160/TH07-01-0064 Bick, 1981, Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome, Ann N Y Acad Sci, 370, 851, 10.1111/j.1749-6632.1981.tb29791.x Gluud, 2008, Systematic review: tranexamic acid for upper gastrointestinal bleeding, Aliment Pharmacol Ther, 27, 752, 10.1111/j.1365-2036.2008.03638.x Shakur, 2010, Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial, Lancet, 376, 23, 10.1016/S0140-6736(10)60835-5 Rivière, 2009, Hereditary Hemorrhagic Telanglectasia and Venous Thromboembolism, Hematology Meeting Reports, 3, 54 Kakar, 2009, Efficacy and Safety of Tranexamic Acid in Control of Bleeding Following TKR: a Randomized Clinical Trial, Indian J Anaesth, 53, 667 Alvarez, 2008, Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied, Transfusion, 48, 519, 10.1111/j.1537-2995.2007.01564.x Shakur, 2010, The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial, Trials, 11, 40, 10.1186/1745-6215-11-40 Dupuis‐Girod, 2012, Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output, JAMA, 307, 948, 10.1001/jama.2012.250